A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma

Inclusion criteria

• Voluntarily participate in the clinical study. Fully understand and get informed of this study and sign the Informed Consent Form (ICF).
• ≥18 years of age on day of signing the informed consent.
• Unresectable locally advanced or metastatic hepatocellular carcinoma as confirmed by histology or cytology.
• Stage B or C based on Barcelona Clinic Liver Cancer (BCLC) staging system; In case of Stage B, subject must be ineligible for surgery and/or local therapy, or has progressed after surgery and/or local therapy or refuses surgery and/or local treatment.
• For Phase Ib, subject has failed after or is unsuitable for the standard systemic therapy against HCC. For Phase II, subject has not previously received systemic therapy.
• At least one measurable lesion as evaluable by RECIST version 1.1.
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1 point.
• A-level Child-Pugh score.
• Expected survival≥3 months.
• For Phase Ib and II, fresh or archived tumor tissue should be provided for analysis in the central laboratory.
• The function of the main organs was basically normal and met the requirements of the protocol.
• For subject with HCV infection, HCV antiviral treatment with the locally approved and available HCV antiviral therapy can be received.
• For subjects with HBV infection, HBV DNA ≤ 2,000 IU/ml at Screening.
• For female subjects of childbearing potential, serum pregnancy test must be negative within 7 days prior to randomization. Except for female subjects who have been recorded as surgically sterilized or who are postmenopausal, female subjects of childbearing potential or male subjects and their partners must agree to use effective contraception from the signature of the informed consent form (ICF) until at least 6 months after the last dose of study drug.

Exclusion criteria

• tumor thrombus in the main portal vein (VP4) by imaging, involving the inferior vena cava or the heart.
• Prior history of hepatic encephalopathy.
• History of liver surgery and/or local treatment for HCC (intervention, ablation therapy, absolute alcohol injection, etc.) or radiotherapy, etc. within 4 weeks prior to first dose.
• Active or documented gastrointestinal bleeding within 6 months (e.g. esophageal or gastric varices, ulcer bleeding).
• Presence of ascites detected by physical examination or clinical symptoms caused by ascites during the screening period, or ascites that need for special treatment, such as repeated drainage, intraperitoneal drug infusion, etc.
• Presence of meningeal metastasis or central nervous system (CNS) metastatic lesions.
• Subject has clinically significant, uncontrolled cardiovascular disease.
• History of definite interstitial lung disease or non-infectious pneumonia except that caused by local radiotherapy; history of active tuberculosis.
• Any serious acute, chronic infections that require systemic antimicrobial, antifungal or antiviral therapy at screening, excluding viral hepatitis.
• Malabsorption syndrome or inability to take the study drug orally for other reasons.
• Had primary malignancies other than HCC within 5 years.
• Subject has had major surgery within 4 weeks prior to first dose (procedures such as central venous cannulation, biopsy, and feeding tube placement are not considered as major surgery).
• Previously received FGFR4 inhibitor treatment.
• Blood transfusion, use of hematopoietic stimulating factors [including G-CSF (granulocyte colony stimulating factor), GM-CSF (granulocyte-macrophage colony stimulating factor), EPO (erythropoietin) and TPO (thrombopoietin)] and human albumin preparations within 14 days prior to first dose.
• Requiring corticosteroids (dose equivalent to > 10 mg/day of Prednisone) or other immunosuppressive drugs within 14 days prior to first dose for systemic therapy.
• Use of traditional Chinese medicine with anti-liver cancer indication within 14 days prior to the firs